BioSpace News Archive

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced enrollment of the first patient into the Phase 3 INVIGORATE Trial of topical ocular reproxalap in patients with allergic conjunctivitis.

JMeds, a Kalos Health Services, LLC company and leader in the medical equipment industry, announced today that it has hired Jenny Swain as its Executive Vice President of Sales and Clinical Initiatives.

InnerScope Hearing Technologies Inc. (OTCQB: INND) (“InnerScope”) a manufacturer and Direct-to-Consumer (“DTC”) distributor/retailer of FDA-Registered Hearing Aids, Personal Sound Amplifiers Products (“Hearing Products”), Hearing Related Treatment Therapies, Doctor-Formulated Dietary Hearing Supplements and proprietary CBD Oil (“Hearing Health Products”) (collectively “Hearing Product Portfolio), today announced its unaudited annual revenue results ended December 31, 2019 of $1,034,791

Emmes today announced that the Food and Drug Administration (FDA) has extended the labeling of ampicillin, a commonly used antibiotic, to include use in infants younger than 28 days in the treatment of serious conditions meningitis and septicemia

Plan Management Corp. (PMC), the long-time leader in the equity benefit plan and cap table management software field, announced today that the latest OptionTrax® software release introduces two major enhancements that make life significantly easier for equity plan and securities administrators.

NorthStar Medical Technologies, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced that it will participate in the upcoming Emerging Medtech Summit 2020 conference, being held February 18 ‒ 20, 2020, in Dana Point, Ca.

Rite Aid Corporation announced the early results of its previously announced offer to exchange up to $600 million aggregate principal amount of its outstanding 6.125% Senior Notes due 2023 for newly issued 7.500% Senior Secured Notes due 2025, upon the terms and subject to the conditions set forth in the offering memorandum dated January 6, 2020.

Propanc Biopharma, Inc. (OTC: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced today that a Certificate for Advance Overseas Finding was received from the Board of Innovation and Science Australia to receive up to a 43.5% “cash back” benefit from overseas R&D expenses.

OncoHost, global leader in host response profiling for improved personalized cancer therapy, together with its partner RayBiotech, a leading life sciences company developing high-throughput protein detection technologies for biomarker discovery initiatives, announced today the companies have been awarded a $1 million grant from the Israel-U.S

Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that Clinicians will provide an update on its Neovasc Reducer™ (“Reducer”) as well as on its Tiara™ (“Tiara”) mitral valve program